fda glp-1 compounding warning october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA alerts health care providers,

However, counterfeiters also leverage technology to create increasingly convincing fake packaging and documentation

Elucidating the metabolic regulation of liver regeneration

At the same time, robust search and personalized suggestions ensure you can jump back to recent picks in a heartbeat, creating a tailored rhythm each time you log in

Food and Drug Administration referred the company to the Department of Justice and threatened to restrict the ingredients that pharmacies mix to make their compounded versions

As of December 7, 2021, 2216 patients have been reported to use anti-TNF therapy alone, of which 2004 patients were rehabilitated without hospitalization, while 10 died with a mortality rate of 3.0.CO;2-L 27